NUTEX HEALTH REPORTS SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2024 FINANCIAL RESULTS
Nutex Health (NASDAQ: NUTX) reported strong financial results for Q2 and H1 2024. Total revenue increased 29% to $76.1 million in Q2 and 25% to $143.5 million in H1 compared to 2023. The Hospital Division saw a 28% increase in visits to 41,208 in Q2. Adjusted EBITDA grew 200% to $12.0 million in Q2 and 159% to $16.6 million in H1. Net loss narrowed to $0.4 million in Q2 from $3.5 million in Q2 2023. The company generated $16.3 million in operating cash flow for H1 2024. Nutex Health operates 21 micro hospitals and HOPDs across 9 states, focusing on increasing cash flow and profitability while driving sustainable growth.
Nutex Health (NASDAQ: NUTX) ha riportato risultati finanziari positivi per il secondo trimestre e il primo semestre del 2024. Il fatturato totale è aumentato del 29% a 76,1 milioni di dollari nel secondo trimestre e del 25% a 143,5 milioni di dollari nel primo semestre rispetto al 2023. La Divisione Ospedaliera ha registrato un aumento del 28% delle visite, raggiungendo 41.208 nel secondo trimestre. L'EBITDA adjusted è cresciuto del 200% a 12,0 milioni di dollari nel secondo trimestre e del 159% a 16,6 milioni di dollari nel primo semestre. La perdita netta si è ridotta a 0,4 milioni di dollari nel secondo trimestre rispetto ai 3,5 milioni di dollari del secondo trimestre 2023. L'azienda ha generato un flusso di cassa operativo di 16,3 milioni di dollari per il primo semestre del 2024. Nutex Health gestisce 21 micro ospedali e HOPD in 9 stati, puntando ad aumentare il flusso di cassa e la redditività, promuovendo nel contempo una crescita sostenibile.
Nutex Health (NASDAQ: NUTX) reportó resultados financieros sólidos para el segundo trimestre y el primer semestre de 2024. Los ingresos totales aumentaron un 29% a 76.1 millones de dólares en el segundo trimestre y un 25% a 143.5 millones de dólares en el primer semestre en comparación con 2023. La División de Hospitales vio un aumento del 28% en las visitas, alcanzando 41,208 en el segundo trimestre. El EBITDA ajustado creció un 200% a 12.0 millones de dólares en el segundo trimestre y un 159% a 16.6 millones de dólares en el primer semestre. La pérdida neta se redujo a 0.4 millones de dólares en el segundo trimestre, desde 3.5 millones de dólares en el segundo trimestre de 2023. La compañía generó 16.3 millones de dólares en flujo de efectivo operativo para el primer semestre de 2024. Nutex Health opera 21 microhospitales y HOPD en 9 estados, enfocándose en aumentar el flujo de efectivo y la rentabilidad mientras impulsa un crecimiento sostenible.
Nutex Health (NASDAQ: NUTX)는 2024년 2분기 및 상반기 강력한 재무 성과를 보고했습니다. 2분기 총 수익은 29% 증가하여 7610만 달러에 달했습니다 및 2023년 대비 상반기 25% 증가하여 1억 4350만 달러에 달했습니다. 병원 부문은 2분기 동안 방문 수가 41,208명으로 28% 증가했습니다. 조정 EBITDA는 2분기 동안 200% 증가하여 1200만 달러에 도달했습니다 및 상반기에는 159% 증가하여 1660만 달러에 달했습니다. 순손실은 2023년 2분기 350만 달러에서 2분기 40만 달러로 축소되었습니다. 이 회사는 2024년 상반기에 운영 현금 흐름으로 1630만 달러를 생성했습니다. Nutex Health는 9개 주에서 21개의 마이크로 병원과 HOPD를 운영하며, 현금 흐름과 수익성을 높이고 지속 가능한 성장을 추진하고 있습니다.
Nutex Health (NASDAQ: NUTX) a rapporté des résultats financiers solides pour le deuxième trimestre et le premier semestre de 2024. Le chiffre d'affaires total a augmenté de 29 % pour atteindre 76,1 millions de dollars au deuxième trimestre et de 25 % pour atteindre 143,5 millions de dollars au premier semestre par rapport à 2023. La division hospitalière a enregistré une augmentation de 28 % des visites, atteignant 41 208 au deuxième trimestre. L'EBITDA ajusté a crû de 200 % pour atteindre 12,0 millions de dollars au deuxième trimestre et de 159 % pour atteindre 16,6 millions de dollars au premier semestre. La perte nette a diminué à 0,4 million de dollars au deuxième trimestre contre 3,5 millions de dollars au deuxième trimestre 2023. L'entreprise a généré un cash-flow opérationnel de 16,3 millions de dollars pour le premier semestre de 2024. Nutex Health opère 21 micro-hôpitaux et HOPD dans 9 États, se concentrant sur l'augmentation du flux de trésorerie et de la rentabilité tout en favorisant une croissance durable.
Nutex Health (NASDAQ: NUTX) berichtete über starke finanzielle Ergebnisse für das zweite Quartal und das erste Halbjahr 2024. Der Gesamtumsatz stieg im zweiten Quartal um 29% auf 76,1 Millionen Dollar und im ersten Halbjahr um 25% auf 143,5 Millionen Dollar im Vergleich zu 2023. Die Krankenhausabteilung verzeichnete einen Anstieg der Besuche um 28% auf 41.208 im zweiten Quartal. Das bereinigte EBITDA wuchs im zweiten Quartal um 200% auf 12,0 Millionen Dollar und um 159% auf 16,6 Millionen Dollar im ersten Halbjahr. Der Nettoverlust verringerte sich im zweiten Quartal auf 0,4 Millionen Dollar nach 3,5 Millionen Dollar im zweiten Quartal 2023. Das Unternehmen erwirtschaftete im ersten Halbjahr 2024 einen operativen Cashflow von 16,3 Millionen Dollar. Nutex Health betreibt 21 Mikkrankenhäuser und HOPD in 9 Bundesstaaten und konzentriert sich darauf, den Cashflow und die Rentabilität zu steigern und gleichzeitig nachhaltiges Wachstum voranzutreiben.
- Total revenue increased 29% to $76.1 million in Q2 2024
- Hospital Division visits grew 28% to 41,208 in Q2 2024
- Adjusted EBITDA increased 200% to $12.0 million in Q2 2024
- Operating cash flow of $16.3 million generated in H1 2024
- Hospital Division operating income grew 140% to $33.3 million in H1 2024
- Net loss of $0.4 million in Q2 2024, though improved from $3.5 million loss in Q2 2023
- Non-cash impairment of assets of $3.5 million in Q2 2024
- Non-cash impairment of goodwill of $3.2 million in Q2 2024
Insights
Nutex Health's Q2 2024 results show strong growth and improved profitability. Key highlights include:
- Total revenue up
29% year-over-year to$76.1 million - Adjusted EBITDA increased
200% to$12.0 million - Hospital division operating income up
150% to$22.8 million - Total visits increased
28% to 41,208
The company's focus on increasing cash flow is evident, with
While revenue growth is impressive, the company still reported a small net loss of
Nutex Health's performance reflects broader trends in the healthcare sector. The
The company's micro-hospital and HOPD model appears to be gaining traction, offering a potential alternative to traditional hospital settings. This aligns with the industry shift towards more accessible, cost-effective care options. However, the healthcare landscape remains competitive and subject to regulatory changes, which could impact future growth.
The population health management division, while smaller, shows steady growth and could become increasingly important as value-based care models gain prominence. Investors should monitor how Nutex leverages its technology platform to integrate clinical and claims data, as this could be a key differentiator in the evolving healthcare ecosystem.
Nutex Health's Q2 results reveal several market trends worth noting. The
The increase in average payment by insurers is a positive sign, potentially reflecting improved negotiating power or a shift in payer mix. The ongoing resolution of NSA claims through the Independent Dispute Resolution process bears watching, as it could impact future revenue stability.
Investor sentiment may be cautiously optimistic, given the strong revenue growth and improved EBITDA. However, the continued net losses and non-cash impairments could raise concerns. The stock's performance will likely depend on Nutex's ability to translate top-line growth into consistent profitability and positive cash flow.
The company's expansion across nine states suggests a scalable model, but investors should monitor integration costs and regional performance variations. Overall, Nutex Health appears well-positioned in the evolving healthcare market, but execution will be key to long-term success.
- TOTAL REVENUE OF
$143.5 MILLION $115.3 MILLION 25% - HOSPITAL DIVISION VISITS OF 81,276 FOR THE FIRST HALF 2024 VS VISITS OF 65,244 FOR THE FIRST HALF 2023, AN INCREASE OF
25% - HOSPITAL DIVISION OPERATING INCOME OF
$33.3 MILLION $13.9 MILLION 140% - NET CASH FROM OPERATING ACTIVITIES OF
$16.3 MILLION - COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW
Financial Highlights for the Three Months Ended June 30, 2024:
- Total revenue of
$76.1 million $58.9 million 29% . Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by13.2% in 2024 compared to the same period in 2023. - Net loss attributable to Nutex Health Inc. of
$0.4 million $3.5 million $3.5 million $3.2 million $3.1 million - EBITDA, attributable to Nutex Health Inc. of
$8.5 million $3.7 million - Adjusted EBITDA, attributable to Nutex Health Inc. of
$12.0 million $4.0 million 200% . - Total visits from the Hospital Division were 41,208 for the second quarter 2024 as compared to 32,183 for the second quarter 2023, an increase of 9,025 or
28.0% . Of this visit growth, mature hospitals increased by10.3% in 2024 compared to the same period in 2023.
Financial Highlights for the Six Months Ended June 30, 2024:
- Total revenue of
$143.5 million $115.3 million 25% . Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by10.0% in 2024 compared to 2023. - Net loss attributable to Nutex Health Inc. of
$0.7 million $8.6 million $3.5 million $3.2 million $5.7 million - EBITDA, attributable to Nutex Health Inc. of
$15.6 million $4.1 million - Adjusted EBITDA, attributable to Nutex Health Inc. of
$16.6 million $6.4 million 159% . - Total visits from the Hospital Division were 81,276 for the six months ended June 30, 2024 as compared to 65,244 for the same period in 2023, an increase of 16,032 or
24.6% . Of this visit growth, mature hospitals increased by9.7% in the six months ended June 30, 2024 compared to the same period in 2023. - Net cash from operating activities of
$16.3 million $422.4 million $40.8 million $22.4 million
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
"We are pleased to report
"Nutex Health is executing extremely well, and we plan to continue to advance our strategic initiatives to drive sustainable growth. We delivered solid revenue growth while accelerating cash flow and strengthening our balance sheet in the first half of 2024. We are confident that we are taking the right steps to lay the foundation for long-term success and to increasing shareholder value," stated Warren Hosseinion, M.D., President of Nutex Health.
"We had a solid Second Quarter with strong year over year growth. Volume continues to increase overall among our hospitals. Our average payment by insurers of patient claims increased, a trend we are optimistic will persist as we continue to work the NSA claims through the Independent Dispute Resolution process," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
For more details on the Company's Second Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the
NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) | ||||||
June 30, 2024 | December 31, 2023 | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 40,807,975 | $ | 22,002,056 | ||
Accounts receivable | 60,658,832 | 58,624,301 | ||||
Accounts receivable - related parties | 4,577,189 | 4,152,068 | ||||
Inventories | 2,759,448 | 3,390,584 | ||||
Prepaid expenses and other current assets | 5,066,994 | 2,679,394 | ||||
Total current assets | 113,870,438 | 90,848,403 | ||||
Property and equipment, net | 78,881,900 | 81,387,649 | ||||
Operating right-of-use assets | 11,690,957 | 11,853,082 | ||||
Finance right-of-use assets | 187,096,271 | 176,146,329 | ||||
Intangible assets, net | 16,180,504 | 20,512,636 | ||||
Goodwill, net | 13,918,719 | 17,066,263 | ||||
Other assets | 764,462 | 431,135 | ||||
Total assets | $ | 422,403,251 | $ | 398,245,497 | ||
Liabilities and Equity | ||||||
Current liabilities: | ||||||
Accounts payable | $ | 16,742,370 | $ | 18,899,196 | ||
Accounts payable - related parties | 6,796,475 | 6,382,197 | ||||
Lines of credit | 2,909,296 | 3,371,676 | ||||
Current portion of long-term debt | 14,223,944 | 10,808,721 | ||||
Operating lease liabilities, current portion | 1,998,512 | 1,579,987 | ||||
Finance lease liabilities, current portion | 5,570,604 | 4,315,979 | ||||
Accrued expenses and other current liabilities | 23,417,191 | 12,955,296 | ||||
Total current liabilities | 71,658,392 | 58,313,052 | ||||
Long-term debt, net | 22,406,516 | 26,314,733 | ||||
Warrant liability | 2,000,714 | - | ||||
Operating lease liabilities, net | 14,690,566 | 15,479,639 | ||||
Finance lease liabilities, net | 226,820,535 | 213,886,213 | ||||
Deferred tax liabilities | 2,804,492 | 5,145,754 | ||||
Total liabilities | 340,381,215 | 319,139,391 | ||||
Commitments and contingencies | ||||||
Equity: | ||||||
Common stock, | 4,988 | 4,511 | ||||
Additional paid-in capital | 472,529,641 | 470,521,218 | ||||
Accumulated deficit | (409,800,662) | (409,072,539) | ||||
Nutex Health Inc. equity | 62,733,967 | 61,453,190 | ||||
Noncontrolling interests | 19,288,069 | 17,652,916 | ||||
Total equity | 82,022,036 | 79,106,106 | ||||
Total liabilities and equity | $ | 422,403,251 | $ | 398,245,497 | ||
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
Revenue: | ||||||||||||
Hospital division | $ | 67,604,878 | $ | 51,611,803 | $ | 127,634,247 | $ | 100,899,967 | ||||
Population health management division | 8,477,383 | 7,312,651 | 15,901,801 | 14,353,904 | ||||||||
Total revenue | 76,082,261 | 58,924,454 | 143,536,048 | 115,253,871 | ||||||||
Operating costs and expenses: | ||||||||||||
Payroll and benefits | 28,398,075 | 24,860,702 | 55,401,219 | 50,697,375 | ||||||||
Contract services | 9,505,222 | 9,747,873 | 20,824,676 | 18,937,204 | ||||||||
Medical supplies | 3,588,464 | 3,264,202 | 8,910,306 | 7,288,084 | ||||||||
Depreciation and amortization | 4,532,804 | 4,169,160 | 8,719,006 | 8,162,907 | ||||||||
Other | 7,496,465 | 7,235,594 | 16,962,432 | 15,673,655 | ||||||||
Total operating costs and expenses | 53,521,030 | 49,277,531 | 110,817,639 | 100,759,225 | ||||||||
Gross profit | 22,561,231 | 9,646,923 | 32,718,409 | 14,494,646 | ||||||||
Corporate and other costs: | ||||||||||||
Facilities closing costs | - | - | - | 217,266 | ||||||||
Stock-based compensation expense | (61,241) | 249,645 | (12,074) | 2,149,645 | ||||||||
Impairment of assets | 3,473,635 | - | 3,473,635 | - | ||||||||
Impairment of goodwill | 3,197,391 | - | 3,197,391 | - | ||||||||
General and administrative expenses | 10,652,390 | 9,759,816 | 19,310,800 | 16,935,360 | ||||||||
Total corporate and other costs | 17,262,175 | 10,009,461 | 25,969,752 | 19,302,271 | ||||||||
Operating income (loss) | 5,299,056 | (362,538) | 6,748,657 | (4,807,625) | ||||||||
Interest expense, net | 5,054,532 | 4,843,048 | 9,498,894 | 7,983,137 | ||||||||
Gain on warrant liability | (3,060,096) | - | (5,660,843) | - | ||||||||
Other (income) expense | (599,502) | (123,528) | (840,694) | 123,927 | ||||||||
Income (loss) before taxes | 3,904,122 | (5,082,058) | 3,751,300 | (12,914,689) | ||||||||
Income tax expense (benefit) | 893,892 | (815,612) | 1,283,557 | (1,726,271) | ||||||||
Net income (loss) | 3,010,230 | (4,266,446) | 2,467,743 | (11,188,418) | ||||||||
Less: net income (loss) attributable to noncontrolling interests | 3,374,278 | (787,399) | 3,195,866 | (2,562,092) | ||||||||
Net loss attributable to Nutex Health Inc. | $ | (364,048) | $ | (3,479,047) | $ | (728,123) | $ | (8,626,326) | ||||
Loss per common share: | ||||||||||||
Basic | $ | (0.07) | $ | (0.79) | $ | (0.15) | $ | (1.98) | ||||
Diluted | $ | (0.07) | $ | (0.79) | $ | (0.15) | $ | (1.98) | ||||
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||
Six Months Ended June 30, | ||||||
2024 | 2023 | |||||
Cash flows from operating activities: | ||||||
Net income (loss) | $ | 2,467,743 | $ | (11,188,418) | ||
Adjustments to reconcile net loss to net cash from operating activities: | ||||||
Depreciation and amortization | 8,719,006 | 8,162,907 | ||||
Gain on warrant liability | (5,660,843) | - | ||||
Impairment of goodwill | 3,197,391 | - | ||||
Impairment of assets | 3,473,635 | - | ||||
Derecognition of goodwill | 453,017 | - | ||||
Stock-based compensation expense | (12,074) | 2,149,645 | ||||
Deferred tax benefit | (2,341,262) | (1,724,111) | ||||
Debt accretion expense | 579,121 | 953,236 | ||||
Loss on lease termination | - | 58,211 | ||||
Non-cash lease expense (income) | (208,423) | 61,734 | ||||
Changes in operating assets and liabilities, net of the effects of acquisitions: | ||||||
Accounts receivable | (2,148,508) | 6,921,239 | ||||
Accounts receivable - related party | (425,121) | (797,058) | ||||
Inventories | 631,136 | 1,082,509 | ||||
Prepaid expenses and other current assets | (1,692,907) | (3,048,993) | ||||
Accounts payable | (1,617,151) | (7,189,929) | ||||
Accounts payable - related party | 414,278 | 3,453 | ||||
Accrued expenses and other current liabilities | 10,481,831 | 5,619,907 | ||||
Net cash from operating activities | 16,310,869 | 1,064,332 | ||||
Cash flows from investing activities: | ||||||
Acquisitions of property and equipment | (1,291,492) | (7,446,902) | ||||
Cash related to sale of business | (711,306) | - | ||||
Cash related to deconsolidation of Real Estate Entities | - | (1,039,157) | ||||
Net cash from investing activities | (2,002,798) | (8,486,059) | ||||
Cash flows from financing activities: | ||||||
Proceeds from lines of credit | 132,167 | 1,949,919 | ||||
Proceeds from notes payable | 4,915,000 | 16,952,905 | ||||
Repayments of lines of credit | (594,547) | (1,592,714) | ||||
Repayments of notes payable | (6,156,543) | (7,481,893) | ||||
Repayments of finance leases | (1,440,016) | (1,870,670) | ||||
Proceeds from common stock issuance, net issuance costs | 9,202,500 | - | ||||
Members' contributions | 300,850 | 649,550 | ||||
Members' distributions | (1,861,563) | (2,686,304) | ||||
Net cash from financing activities | 4,497,848 | 5,920,793 | ||||
Net change in cash and cash equivalents | 18,805,919 | (1,500,934) | ||||
Cash and cash equivalents - beginning of the period | 22,002,056 | 34,255,264 | ||||
Cash and cash equivalents - end of the period | $ | 40,807,975 | $ | 32,754,330 | ||
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||
Reconciliation of net loss attributable to Nutex Health Inc. to Adjusted EBITDA: | ||||||||||||
Net loss attributable to Nutex Health Inc. | $ | (364,048) | $ | (3,479,047) | $ | (728,123) | $ | (8,626,326) | ||||
Depreciation and amortization | 4,532,804 | 4,169,160 | 8,719,006 | 8,162,907 | ||||||||
Interest expense, net | 5,054,532 | 4,843,048 | 9,498,894 | 7,983,137 | ||||||||
Income tax expense (benefit) | 893,892 | (815,612) | 1,283,557 | (1,726,271) | ||||||||
Allocation to noncontrolling interests | (1,627,829) | (972,655) | (3,172,002) | (1,727,965) | ||||||||
EBITDA attributable to Nutex Health Inc. | 8,489,351 | 3,744,894 | 15,601,332 | 4,065,482 | ||||||||
Facilities closing costs | - | - | - | 217,266 | ||||||||
Gain on warrant liability | (3,060,096) | - | (5,660,843) | - | ||||||||
Impairment of assets | 3,473,635 | 3,473,635 | ||||||||||
Impairment of goodwill | 3,197,391 | - | 3,197,391 | - | ||||||||
Stock-based compensation expense | (61,241) | 249,645 | (12,074) | 2,149,645 | ||||||||
Adjusted EBITDA attributable to Nutex Health Inc. | $ | 12,039,040 | $ | 3,994,539 | $ | 16,599,441 | $ | 6,432,393 | ||||
About Nutex Health Inc.
Headquartered in
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in nine states.
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.
Forward-Looking Statements
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Report on Form 10-Q for the period ended March 31, 2024 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-second-quarter-and-six-months-ended-june-30-2024-financial-results-302218405.html
SOURCE Nutex Health, Inc.
FAQ
What was Nutex Health's (NUTX) revenue growth in Q2 2024?
How much did Nutex Health's (NUTX) Hospital Division visits increase in Q2 2024?
What was Nutex Health's (NUTX) Adjusted EBITDA for Q2 2024?
How much operating cash flow did Nutex Health (NUTX) generate in H1 2024?
